Limin Group Co.,Ltd. (SHE:002734)

Market Cap	7.17B +41.5%
Revenue (ttm)	4.64B +4.2%
Net Income	503.80M +154.5%
EPS	1.15 +116.0%
Shares Out	471.62M
PE Ratio	13.21
Forward PE	12.26
Dividend	0.45 (2.96%)
Ex-Dividend Date	May 22, 2026

Volume	12,067,300
Open	16.30
Previous Close	15.25
Day's Range	14.88 - 16.30
52-Week Range	14.97 - 24.87
Beta	0.78
Analysts	Strong Buy
Price Target	20.00 (+31.58%)
Earnings Date	Aug 14, 2026

About Limin Group

Limin Group Co.,Ltd. engages in the research and development, production, and sale of fungicides, insecticides, and herbicides in China. The company offers technical, single formulation, and mixture of fungicide, insecticide, herbicide, nematicide, and acaricide. It also provides veterinary drugs, including Azoxystrobin 97% TC, Captan 95% TC, Chlorothalonil 98% TC, Cymoxanil 98% TC, Cyprodinil 95% TC, Difenoconazole 95% TC, Famoxadone 98% TC, Folpet 95% TC, Fosetyl-al 96% TC, Mancozeb 88% TC, Mancozeb 96% TC, Metiram 85% TC, Metiram 87% TC, Met...

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 1996
• Employees: 4,593
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002734

Financial Performance

In 2025, Limin Group's revenue was 4.53 billion, an increase of 6.83% compared to the previous year's 4.24 billion. Earnings were 479.76 million, an increase of 489.70%.